Condition: Alzheimer Disease · Agitation in Dementia · Sponsor: Bernard (Barry) Baumel
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
This description comes directly from the study's public registry record.
Bernard Baumel, MD · (305) 243-3100 · mep980@miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami Department of Neurology | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06781333